List view / Grid view
2 September 2013 | By Roche
Roche announced that a new injectable (subcutaneous) formulation of Herceptin (trastuzumab) has been approved by the European Commission...
2 September 2013 | By Boehringer Ingelheim
Results from TIOSPIR™ will be presented for the first time at the Annual Congress of the European Respiratory Society...
2 September 2013 | By AstraZeneca
SAVOR provides information on cardiovascular safety for Onglyza in the wake of past questions about cardiovascular safety of type 2 diabetes treatments...
1 September 2013 | By Daiichi Sankyo
Daiichi Sankyo announced results from the global phase 3 Hokusai-VTE study...
1 September 2013 | By Amgen
Results of analyses presented at ESC Congress 2013...
31 August 2013 | By Pfizer
Results presented at the ESC Congress 2013...
30 August 2013 | By Sanofi
Sanofi and its subsidiary Genzyme announced that the European Commission has granted marketing authorization for Aubagio® (teriflunomide)...
30 August 2013 | By Teva Pharmaceutical Industries Ltd
TEVA announced top-line results of its final Phase III clinical study for armodafinil (NUVIGIL®)...
30 August 2013 | By Abbott
Analysis of more than 1 million adult hospital cases revealed 21 percent reduction in length of hospital stay and cost with nutritional intervention...
29 August 2013 | By Daiichi Sankyo
Daiichi Sankyo has filed an application for approval in Japan to manufacture and market RANMARK®...
29 August 2013 | By Sanofi
Sanofi announces that it has successfully priced its offering of EUR 1 billion of notes, due 2020, bearing interest at an annual rate of 1.875%...
28 August 2013 | By IMBA - Institute of Molecular Biotechnology GmbH
Complex human brain tissue has been successfully developed in a three-dimensional culture system established in an Austrian laboratory...
28 August 2013 | By Carbon Trust
ABPI collaborates with the Carbon Trust to help pharmaceutical companies quickly estimate the carbon footprint of tablet medicines distributed in blister packs...
27 August 2013 | By Amgen
Amgen will present new data on omecamtiv mecarbil, a small molecule cardiac myosin activator that is being studied for the treatment of heart failure in collaboration with Cytokinetics...
26 August 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announced the upcoming presentation of new data on the novel oral anticoagulant (NOAC) Pradaxa® (dabigatran etexilate) during the ESC Congress 2013...
